News

Video

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory CLL/SLL: Results From the Phase 1 BGB-16673-101 Study

Author(s):

Ricardo D. Parrondo, MD

BGB-16673-101 (NCT05006716) is a phase 1 study of a bruton tyrosine kinase degrader (BGB-16673) in patients with relapsed or refractory CLL/SLL.

Related Videos
Elacestrant real-world progression-free survival (rwPFS) of adult patients with ER+/HER2-, advanced breast cancer: a retrospective analysis using insurance claims in the United States
DB-12
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
5-Year Follow-Up of Cohort 1 from the SEQUOIA Study
Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
RMC-9805
LGSOC 2024
Eunice S. Wang, MD
Related Content
Orca-Q in Hematologic Malignancies | Image Credit: © Tatiana Shepeleva - stock.adobe.com
December 16th 2024

Orca-Q Leads to Low Rates of GVHD, Non-Relapse Mortality in High-Risk Hematologic Malignancies After Allo-HCT

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

ASH Annual Meeting | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 12th 2024

Iopofosine I 131 Is Efficacious, Tolerable in Heavily Pretreated R/R Waldenström Macroglobulinemia

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

HMA-Naive Chronic Myelomonocytic Leukemia | Image credit: © Nittaya – stock.adobe.com
December 11th 2024

IO-202 Plus Azacitidine Elicits Responses in HMA-Naive Chronic Myelomonocytic Leukemia

Polycythemia Vera | Image Credit: © ChaoticMind – stock.adobe.com
December 11th 2024

NFKB1 Haplotype Decreases Inflammation, Increases Response to Ropeginterferon Alfa-2b in PV and ET